Moderna Developing mRNA Vaccines for Diseases Linked to COVID Shots

As Moderna expands its mRNA vaccine pipeline to target Epstein-Barr, shingles, cancer and autoimmune diseases,…

Children's Health Defense

During its Vaccines Day Event for investors on March 28, Moderna announced progress on multiple mRNA-based vaccines and therapeutic candidates in its “pipeline.”

Three vaccines targeting Epstein-Barr virus (EBV), Varicella-zoster virus (VZV, chickenpox and shingles) and Norovirus are advancing to “pivotal late-stage development,” the company said.

Moderna also announced that the U.S. Food and Drug Administration (FDA) is expected to approve its respiratory syncytial virus (RSV) vaccine mRNA-1345 for older adults. This is part of an expected $52 billion market for Moderna’s infectious disease vaccines.

“We continue to explore the application of mRNA in the potential treatment of cardiovascular and other ischemic vascular diseases,” Moderna’s website states in its product plans for therapeutic areas.

The company also is developing mRNA solutions for cancer and autoimmune diseases.

Citing the well-documented and often serious adverse reactions to the COVID-19 mRNA vaccines, some scientists and doctors said they are concerned about the dangers of existing and new mRNA formulations.

They also question whether Moderna is attempting to profit from solutions for diseases its products are causing.

Blocking the ‘foot soldiers of the immune system’

Synthetic-modified RNA (modRNA) in the cells suppresses innate immunity that keeps latent viruses at bay and protects against new infections, according to Brian Hooker, Ph.D., chief scientific officer at Children’s Health Defense.

“One of the mechanisms involves microRNAs that suppress the production of cellular interferon, which is extremely important for attack against viral infections as well as tumor suppression,” Hooker told The Defender.

Hooker pointed to the June 2022 paper by Stephanie Seneff, Ph.D., Dr. Peter McCullough and others that explored innate immune suppression by mRNA vaccines.

The authors proposed that vaccine-induced interferon suppression blocks the proper functioning of CD8+ T cells — often called the foot soldiers of the immune system — allowing dormant viruses to reactivate and, in the case of VZV, to cause shingles, the “adult” version of chickenpox.

A 2021 paper reported 54 cases of herpes zoster (shingles) emerging an average of 7 days after COVID-19 vaccination. A 2022 paper reported 10 cases of herpes zoster reactivation within one to three weeks after COVID-19 vaccination.

Yet the authors of both papers claimed a definitive link between the vaccines and the symptoms could not be established.

French scientist Hélène Banoun, Ph.D., in “La Science face au Pouvoir: Ce que révèle la crise Covid-19 sur la biopolitique du XXIe siècle” (“Science versus Power: What the Covid-19 crisis reveals about 21st-century biopolitics”), wrote that the disorganization of the innate immune system and its receptors contribute to the reactivation of latent viruses — including herpes, shingles, human papillomavirus (HPV) and RSV.

Many people infected by EBV or VZV become healthy, asymptomatic carriers, according to Banoun.

“These viruses, as well as other viruses or bacteria — such as the Koch bacillus responsible for tuberculosis — can remain dormant throughout life, or be reactivated during immunosuppression,” Banoun told The Defender.

Banoun also cited leprosy reactions following mRNA injections observed in numerous countries. “Despite the sophistication of mRNA vaccines, some side effects apparently reactivate diseases thought to have been relegated to the past,” she wrote.

Numerous case studies (here, here and here) correlate the development of EBV-related symptoms and antibodies with COVID-19 mRNA vaccines.

Matthew Matlock, a combat veteran and Ironman athlete, self-reported at the April 2022 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee that he suffered from the reactivation of EBV, in addition to cardiac and mast cell disease issues, after receiving the second dose of Pfizer’s COVID-19 shot.

Moderna is creating two versions of a vaccine for EBV: mRNA-1189 for prevention and mRNA-1195 to address the long-term effects, specifically multiple sclerosis and a subcategory of lymphoma in solid organ transplant patients.

Moderna reportedly paused its EBV vaccine trial last year when a subject developed myocarditis.

Moderna does not mention other long-term EBV effects such as chronic active EBV, EBV-associated cancers, anemia, rupture of the spleen, thrombocytopenia, hepatitis, myocarditis and diseases of the nervous system including encephalitis, meningitis and Guillain-Barré syndrome.

Moderna CEO Stéphane Bancel said the market for the EBV vaccines is expected to be several billion dollars…